Európska únia - slovenčina - EMA (European Medicines Agency)

astrazeneca ab - roflumilast - pľúcna choroba, chronická obštrukcia - drogy obštrukčnej choroby dýchacích ciest, - daliresp je indikovaná na udržiavaciu liečbu ťažkou chronickou obštrukčnou chorobou pľúc (chochp) (fev1 po bronchodilatátor menej ako 50% predpokladanej) spojená s chronickou bronchitídou u dospelých pacientov s anamnézou častých exacerbácií ako doplnku na bronchodilatačná liečba.

Európska únia - slovenčina - EMA (European Medicines Agency)

astrazeneca ab - roflumilast - pľúcna choroba, chronická obštrukcia - drogy obštrukčnej choroby dýchacích ciest, - libertek je indikovaná na udržiavaciu liečbu ťažkou chronickou obštrukčnou chorobou pľúc (chochp) (fev1 po bronchodilatátor menej ako 50% predpokladanej) spojená s chronickou bronchitídou u dospelých pacientov s anamnézou častých exacerbácií ako doplnku na bronchodilatačná liečba.

Európska únia - slovenčina - EMA (European Medicines Agency)

teva pharma b.v. - mykofenolát mofetil - odmietnutie štepu - imunosupresíva - mykofenolát mofetilu teva je indikovaný v kombinácii s cyklosporínom a kortikosteroidmi na prevenciu akútneho transplantátu u pacientov užívajúcich alogénnej transplantácii obličiek, srdca alebo pečene.

Európska únia - slovenčina - EMA (European Medicines Agency)

teva b.v. - mykofenolát mofetil - odmietnutie štepu - imunosupresíva - myfenax je indikovaný v kombinácii s cyklosporínom a kortikosteroidmi na prevenciu akútneho transplantátu u pacientov užívajúcich alogénnej transplantácii obličiek, srdca alebo pečene.

Európska únia - slovenčina - EMA (European Medicines Agency)

pfizer ltd. - sitaxentan sodný - hypertenzia, pľúca - antihypertenzív, - liečba pacientov s pľúcnou arteriálnou hypertenziou (pah), ktorá je klasifikovaná ako funkčná trieda iii svetovej zdravotníckej organizácie (who), s cieľom zlepšiť výkonovú kapacitu. Účinnosť bola preukázaná pri primárnej pľúcnej hypertenzii a pľúcnej hypertenzii spojenej s ochorením spojivového tkaniva.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

vulm s.r.o., slovensko - mliečnan horečnatý - 39 - soli a ionty pro p.o. a parent. aplikÁciu

Európska únia - slovenčina - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artritída, reumatoidná artritída - imunosupresíva - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant sa môže používať ako monoterapia alebo v kombinácii s metotrexátom. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Európska únia - slovenčina - EMA (European Medicines Agency)

pfizer europe ma eeig - crizotinib - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.

Európska únia - slovenčina - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artritída, reumatoidná artritída - imunosupresíva - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 a 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

wÖrwag pharma gmbh & co.kg, nemecko - síran železnatý a kyselina listová - 12 - antianaemica